Aurobindo Pharma Appoints RPR & Associates as Secretarial Auditor

1 min read     Updated on 22 May 2026, 01:39 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Aurobindo Pharma Limited has accepted the resignation of M/s. MRR & Associates as Secretarial Auditor effective May 22, 2026, due to health issues. The board has appointed M/s. RPR & Associates as the new Secretarial Auditors for a term of five consecutive years from FY 2026-27 to FY 2030-31, pending shareholder approval.

powered bylight_fuzz_icon
40939503

*this image is generated using AI for illustrative purposes only.

Aurobindo Pharma Limited has announced a change in its secretarial auditor following a board meeting held on May 21, 2026. The company accepted the resignation of its existing auditor, M/s. MRR & Associates, effective from May 22, 2026. The resignation was attributed to health issues concerning the firm's sole proprietor.

Consequently, the board approved the appointment of M/s. RPR & Associates, Company Secretaries in Practice, as the new Secretarial Auditors. The appointment is for a term of five consecutive years, commencing from FY 2026-27 and extending to FY 2030-31. This decision is subject to the approval of shareholders at the ensuing Annual General Meeting.

Details of the Change

The transition involves the cessation of the previous firm and the onboarding of a new entity to ensure compliance with regulatory requirements. The board meeting, which commenced at 4:30 p.m. and concluded at 6:25 p.m., reviewed the necessary disclosures pursuant to Regulation 30 of the SEBI Listing Regulations.

Key Particulars of Appointment

Particulars Details
New Firm M/s. RPR & Associates
Firm Registration No. S2017TL469100
Appointment Date May 21, 2026
Term Five consecutive years (FY 2026-27 to FY 2030-31)
Resignation Effective Date May 22, 2026

Profile of New Auditor

M/s. RPR & Associates is a peer-reviewed firm of company secretaries in practice. The firm specializes in delivering professional services across Corporate Laws, SEBI Regulations, and FEMA Regulations. Its expertise includes conducting Secretarial Audits, Due Diligence Audits, and Compliance Audits. The proprietor, Mr. Y. Ravi Prasada Reddy, has over 23 years of experience as a practicing Company Secretary.

Historical Stock Returns for Aurobindo Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-5.38%-3.14%+5.16%+21.36%+21.54%+44.45%

How might shareholders respond to the appointment of M/s. RPR & Associates at the upcoming Annual General Meeting, and are there any potential risks of the resolution not being approved?

Could the abrupt transition in secretarial auditors create any compliance gaps or delays in Aurobindo Pharma's regulatory filings with SEBI during the handover period?

Given M/s. RPR & Associates' specialization in FEMA Regulations, does this appointment signal that Aurobindo Pharma may be planning increased cross-border transactions or international expansion activities?

Aurobindo Pharma Extinguishes 54,23,728 Equity Shares Under ₹800 Crore Buyback Programme

3 min read     Updated on 19 May 2026, 07:10 AM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Aurobindo Pharma Limited extinguished 54,23,728 equity shares on May 14, 2026, under its tender offer buyback conducted at ₹1,475 per share for an aggregate amount not exceeding ₹800,00,00,000. All extinguished shares were in dematerialised form, with confirmations received from both NSDL and CDSL. The company's paid-up share capital has been reduced from 58,08,01,623 equity shares to 57,53,77,895 equity shares of ₹1/- each following the extinguishment. The process was carried out in compliance with the SEBI (Buy-Back of Securities) Regulations, 2018.

powered bylight_fuzz_icon
40700416

*this image is generated using AI for illustrative purposes only.

Aurobindo Pharma Limited has formally completed the extinguishment of 54,23,728 fully paid-up equity shares of ₹1/- face value each, as part of its buyback programme conducted through the tender offer route. The extinguishment was executed on May 14, 2026, and the company notified the stock exchanges on May 15, 2026, in compliance with Regulations 11 and 24(iv) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018.

Buyback Programme Overview

The buyback was carried out at a price of ₹1,475 per equity share, for an aggregate amount not exceeding ₹800,00,00,000 (Rupees Eight Hundred Crore only), on a proportionate basis through the tender offer route. The tendering period opened on Thursday, April 23, 2026, and closed on Wednesday, April 29, 2026 (both days inclusive). The process was initiated pursuant to the Public Announcement dated Tuesday, April 7, 2026, published on Wednesday, April 8, 2026, and the Letter of Offer dated Tuesday, April 21, 2026.

Share Capital Reconciliation

The extinguishment of 54,23,728 equity shares — all in dematerialised form — has resulted in a reduction in the company's issued, subscribed, and fully paid-up share capital. The following table presents the pre- and post-extinguishment share capital position:

Particulars: No. of Equity Shares Amount (in ₹)
Pre-extinguishment paid-up capital 58,08,01,623 Equity Shares of ₹1/- each 58,08,01,623
Less: Shares bought back (Dematerialised Form) 54,23,728 54,23,728
Less: Shares bought back (Physical Form) Nil Nil
Post-extinguishment paid-up capital 57,53,77,895 Equity Shares of ₹1/- each 57,53,77,895

Depository Confirmations

Confirmations of the extinguishment were received from both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) on May 14, 2026. NSDL confirmed the debit of 5,423,728.000 equity shares (ISIN: INE406A01037) from the company's account held with Stock Holding Corporation of India Limited (DP ID: IN301330, Client ID: 40630602), with an execution date of May 13, 2026. CDSL similarly confirmed the buyback of 5423728 equity shares, noting that the capital of the company after the buyback as recorded with CDSL stands at Rs. 575377895/- (Equity Shares of Rs.1/- each).

Shareholding Pattern: Pre and Post Buyback

The extinguishment has resulted in a marginal shift in the shareholding pattern of the company. The table below presents the pre- and post-buyback shareholding distribution:

Category: Pre-Buyback Shares Pre-Buyback (%) Post-Buyback Shares Post-Buyback (%)
Promoter & Promoter Group and persons acting in concert 30,09,48,721 51.82 29,85,22,726 51.88
Non-Promoter Shareholding 27,98,52,902 48.18 27,68,55,169 48.12
— Foreign Investors (OCBs/FIIs/NRIs/Non-residents/Non-domestic companies) 9,06,24,695 15.60 — —
— Indian Financial Institutions/Banks/Mutual Funds/Government Companies 14,50,76,920 24.98 — —
— Others (Individuals, Bodies Corporate, Employees, etc.) 4,41,51,287 7.60 — —
Total 58,08,01,623 100.00 57,53,77,895 100.00

Pre-buyback figures are as on the Record Date. Post-buyback figures reflect extinguishment of 54,23,728 equity shares accepted in the Buyback.

Regulatory Compliance and Certification

A certificate of extinguishment dated May 15, 2026, was issued in compliance with Regulation 11(iii) of the Buyback Regulations, signed by the Managing Director K. Nithyananda Reddy, Whole-time Director M. Madan Mohan Reddy, and Company Secretary & Compliance Officer B. Adi Reddy. The certificate was also attested by the Secretarial Auditor, MRR & Associates, Company Secretaries, and KFin Technologies Limited, the Registrar to the Buyback. Axis Capital Limited served as the Manager to the Buyback. The company has submitted copies of the depository confirmation letters, the extinguishment certificate, and the pre- and post-buyback shareholding pattern to the stock exchanges as required under the applicable regulations.

Historical Stock Returns for Aurobindo Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-5.38%-3.14%+5.16%+21.36%+21.54%+44.45%

How might the reduction in outstanding shares impact Aurobindo Pharma's earnings per share and valuation multiples in upcoming quarterly results?

Will the ₹800 crore capital deployment for buybacks signal a shift in Aurobindo Pharma's capital allocation strategy, potentially reducing future investments in R&D or capacity expansion?

Could the marginal increase in promoter shareholding percentage post-buyback indicate intentions for further stake consolidation or future open market purchases?

More News on Aurobindo Pharma

1 Year Returns:+21.54%